Wed, May 15, 12:27 PM (245 days ago)
ZyVersa Therapeutics, Inc. filed an amendment (Form 10-K/A) to its Annual Report for the fiscal year ended December 31, 2023, originally filed on March 25, 2024. This amendment addresses and restates Item 9A of Part II and Item 15 of Part IV to clarify existing language and update the number of outstanding shares as of May 10, 2024. It includes new certifications by the principal executive and financial officers under Section 302 of the Sarbanes-Oxley Act. The amendment does not modify any financial statements or other information from the original filing. Key Points: - The amendment clarifies language in Item 9A and updates the exhibit list in Item 15. - Disclosure controls and procedures were deemed ineffective due to a material weakness in business process controls. - Management is implementing a remediation plan to address these weaknesses in 2024. - No financial statements are included in this amendment. - ZyVersa remains an emerging growth company under the JOBS Act, utilizing certain reduced reporting requirements. This amendment should be read in conjunction with the original 2023 10-K and subsequent filings.